2nd Quarter - Termination
THE MCMANUS GROUP for FULCRUM THERAPEUTICS
Firm
Client
Income
$60,000
Expenses
—
Terminated
Jun 30, 2026
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARY GRACE DARCEY | — |
| JOHN MCMANUS | — |
| ABIGAIL SMITH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.